Experiencing Danny Elfman on Acid: A Coachella Story
Famed film composer returns to rock roots for a masterful, mind-melting Coachella set, and I was fortunate to catch it while tripping on LSD.
Psychedelic Spotlight News
Understanding 3 Risks of Investing in Psychedelic Stocks
No one is responsible for your financial future, other than yourself, so be responsible with your money.
Psychedelic Business Spotlight – April 22
This week in psychedelic business news: Mindset Pharma files a new patent; Ehave’s MetaHealthU app seeks to cure HPPD; Wellbeing Digital Sciences contemplates a sale.
Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
Our resident Psychedelic Investor James Hallifax wonders if the “Shark Tank” star’s prediction makes financial sense.
5 Examples of Ancient Psychedelic Cave Art
Ancient civilizations have been using psychedelic substances, like psilocybin, for millenniums, and the proof is in their cave art.
5 Fiercely Psychedelic Songs (Not From the ’60s)
Here are five deliciously trippy songs to add to your next psychedelic playlist before embarking on a journey toward ego death.
Psychedelic Business Spotlight – April 15
This week in psychedelic business news: The industry’s first major merger; NeonMind launches clinics; a portfolio of patents is acquired.
Why Investors Should Care About MindMed’s LSD Trial for Anxiety
MindMed will present preliminary results from a Phase 2a study treating Generalized Anxiety Disorder with LSD therapy next month.
3 Most Promising Psychedelics for Mental Health Breakthroughs
Psychiatrist, researcher, and CEO of Zylorion Health, Dr. Peter Silverstone, ranks psychedelic medicines based on their potential to revolutionize mental health treatment.
Numinus Acquires Novamind: What Does This Mean for the Psychedelic Industry? | NUMI, NM
Numinus Acquiring Novamind in First Major Psychedelics Merger
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Not only will this be your chance to meet me, but also the legendary Paul Stamets!
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Back to Numinus
This acquisition will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.
Psychedelic stock investors woke up to some major news today: Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) announced that they are acquiring Novamind Inc. (CSE: NM) (OTCQB: NVMDF).
The acquisition will be done in stock, and shareholders of Novamind will receive 0.84 of a common share of Numinus per Novamind share held, implying an offer price of $0.44 per Novamind share. This means Numinus is offering a premium of 51% to Novamind shareholders, based on the 20-day volume-weighted average price of their stock. When the transaction is completed, Novamind shareholders will own around 18% of Numinus.
If you currently hold Novamind stock, you do not need to do anything. When the transaction is finalized, each Novamind share you own will automatically be transformed into 0.84 of a Numinus share.
#Numinus #NovaMind #psychedelicStocks
End of content
End of content